Payment overview · 2025
General Payments
$879.04
50 reported records · 14 companies
Healthcare provider profile · identity verified
Mitchell Louis Keel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FARMINGTON, NM · NPI 1114480209
Verified facts
What the public records show
CMS Open Payments records show Mitchell Louis Keel, MD received $879.04 in general payments during 2025 across 50 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 27.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 359 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $243.40 | 27.7% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $187.79 | 21.4% | 18 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $133.65 | 15.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $51.77 | 5.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.93 | 4.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $38.41 | 4.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.73 | 3.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.86 | 3.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.78 | 3.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.49 | 3.2% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $16.45 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.17 | 1.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.50 | 1.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.11 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $769.96 | 48 |
| Education | $109.08 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $295.17 | 13 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $151.64 | 15 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $133.65 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.93 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.93 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $38.41 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.73 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.86 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.78 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.80 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.57 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 196 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 80 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 81 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
105 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
359 | 46 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
66 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
155 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
196 | 24 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 610 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 478 | 96 |
| Gabapentin | Gabapentin | 475 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 470 | 82 |
| Lisinopril | Lisinopril | 467 | 105 |
| Metformin Hcl | Metformin Hcl | 459 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 421 | 92 |
| Potassium Chloride | Potassium Chloride | 369 | 81 |
| Furosemide | Furosemide | 366 | 89 |
| Eliquis | Apixaban | 359 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 354 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 324 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 304 | 55 |
| Omeprazole | Omeprazole | 302 | 69 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 282 | 75 |
| Losartan Potassium | Losartan Potassium | 280 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 255 | 68 |
| Trazodone Hcl | Trazodone Hcl | 217 | 50 |
| Carvedilol | Carvedilol | 214 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 211 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 209 | 33 |
| Sertraline Hcl | Sertraline Hcl | 202 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 201 | 36 |
| Mirtazapine | Mirtazapine | 200 | 33 |
| Mounjaro | Tirzepatide | 196 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 39 |
| Simvastatin | Simvastatin | 192 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 185 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 60 |
| Meloxicam | Meloxicam | 182 | 39 |
| Lorazepam | Lorazepam | 176 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 175 | 75 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 31 |
| Jardiance | Empagliflozin | 155 | 27 |
| Olanzapine | Olanzapine | 153 | 27 |
| Donepezil Hcl | Donepezil Hcl | 147 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 144 | 24 |
| Memantine Hcl | Memantine Hcl | 135 | 22 |
| Allopurinol | Allopurinol | 132 | 28 |
| Glipizide Er | Glipizide | 114 | 33 |
| Sucralfate | Sucralfate | 110 | 23 |
| Tramadol Hcl | Tramadol Hcl | 109 | 23 |
| Metformin Hcl Er | Metformin Hcl | 108 | 28 |
| Farxiga | Dapagliflozin Propanediol | 105 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 105 | 22 |
| Prednisone | Prednisone | 105 | 78 |
| Buspirone Hcl | Buspirone Hcl | 104 | 24 |
| Cefdinir | Cefdinir | 103 | 71 |
| Divalproex Sodium | Divalproex Sodium | 99 | 16 |
| Spironolactone | Spironolactone | 99 | 24 |
| Ezetimibe | Ezetimibe | 97 | 23 |
| Montelukast Sodium | Montelukast Sodium | 95 | 19 |
| Pregabalin | Pregabalin | 92 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 20 |
| Alendronate Sodium | Alendronate Sodium | 84 | 14 |
| Famotidine | Famotidine | 82 | 23 |
| Levetiracetam | Levetiracetam | 81 | 16 |
| Rybelsus | Semaglutide | 81 | 17 |
| Ondansetron Odt | Ondansetron | 80 | 48 |
| Rexulti | Brexpiprazole | 80 | suppressed |
| Nifedipine Er | Nifedipine | 79 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 20 |
| Ozempic | Semaglutide | 78 | 18 |
| Promethazine Hcl | Promethazine Hcl | 77 | 23 |
| Januvia | Sitagliptin Phosphate | 75 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 11 |
| Risperidone | Risperidone | 69 | 11 |
| Azithromycin | Azithromycin | 68 | 59 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 14 |
| Atenolol | Atenolol | 65 | 16 |
| Xarelto | Rivaroxaban | 65 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 15 |
| Fluconazole | Fluconazole | 61 | 37 |
| Lamotrigine | Lamotrigine | 61 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 60 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 58 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 56 | 16 |
| Finasteride | Finasteride | 56 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 16 |
| Clonazepam | Clonazepam | 55 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 47 |
| Diazepam | Diazepam | 54 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 12 |
| Baclofen | Baclofen | 50 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 50 | 15 |
| Topiramate | Topiramate | 49 | 11 |
| Zaleplon | Zaleplon | 49 | suppressed |
| Aripiprazole | Aripiprazole | 48 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | suppressed |
| Alprazolam | Alprazolam | 46 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | 12 |
| Ibuprofen | Ibuprofen | 46 | 14 |
| Propranolol Hcl | Propranolol Hcl | 46 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | suppressed |
| Estradiol | Estradiol | 43 | suppressed |
| Celecoxib | Celecoxib | 42 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 30 |
| Glimepiride | Glimepiride | 40 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | 13 |
| Bumetanide | Bumetanide | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Sotalol | Sotalol Hcl | 39 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 38 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 36 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Haloperidol | Haloperidol | 33 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 23 |
| Latanoprost | Latanoprost | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 23 |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 24 |
| Methimazole | Methimazole | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 24 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 24 | suppressed |
| Insulin Lispro | Insulin Lispro | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | 11 |
| Nystatin | Nystatin | 24 | 14 |
| Torsemide | Torsemide | 24 | suppressed |
| Xifaxan | Rifaximin | 24 | suppressed |
| Humalog | Insulin Lispro | 23 | suppressed |
| Levemir | Insulin Detemir | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 11 |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $879.04 · 50 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COBENFY, Cologuard Collection Kit, MOUNJARO, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error